<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01167218</url>
  </required_header>
  <id_info>
    <org_study_id>09318</org_study_id>
    <nct_id>NCT01167218</nct_id>
  </id_info>
  <brief_title>Study to Assess Platelet Dysfunction With Verify Now Assay</brief_title>
  <official_title>&quot;In-vitro Characterization of Platelet Dysfunction in Common Hematological Disorders Using the Verify Now Assay&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to conduct a Verify now assay to detect platelet aggregation
      defects in patients with Myelodysplastic syndrome(MDS), immune thrombocytopenia purpura (ITP)
      and myeloproliferative disorders (MPD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Verify Now is a rapid, simple, point-of service assay to measure platelet aggregation. The
      verify now assay is designed to assess platelet function based on the ability of activated
      platelets to bind fibrinogen. It is hoped that this study will detect the subtle platelet
      functional abnormalities in patients with hematological disorders.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>platelet aggregation defects</measure>
    <time_frame>one year</time_frame>
    <description>to assess platelet aggregation defects</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">79</enrollment>
  <condition>Platelet Aggregation Defects</condition>
  <arm_group>
    <arm_group_label>verify now assay</arm_group_label>
    <description>subjects who have Myelodysplastic syndrome, immune thrombocytopenia, and myeloproliferative disorders with platelet disorders</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients with platelet defects
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

        - Patients with common blood disorders such as immune thrombocytopenia purpura(ITP)
        myelodysplastic syndrome MDS)and myeloproliferative disorders (MPV)

        Exclusion Criteria

        - Patients with normal platelet counts
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nina D'abreo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Winthrop University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Winthrop University Hospital Oncology/Hematology Division</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>July 19, 2010</study_first_submitted>
  <study_first_submitted_qc>July 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2010</study_first_posted>
  <last_update_submitted>February 4, 2019</last_update_submitted>
  <last_update_submitted_qc>February 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>verify now assay for hematological disorders</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

